Glenmark readies for launch of Napo's crofelemer
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals is preparing for the launch of Napo Pharmaceuticals' novel anti-secretory gastrointestinal agent, crofelemer, in 140 emerging and developing world countries, following positive Phase III results for the product for the treatment of chronic diarrhoea in people living with HIV/AIDS.